CM336 for multiple myeloma after prior treatments
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can do most daily activities (ECOG 0–2, usually meaning you’re up and about).
- Your multiple myeloma has come back or is not responding to treatment.
- You’ve already tried at least 2 prior myeloma treatments.
- Those prior treatments must include a proteasome inhibitor, an immune-modulating pill (IMiD), and an anti-CD38 antibody (if available).
- You have NOT had treatment that targets BCMA, including BCMA-targeted therapy.
- You have NOT had CAR-T therapy and have not had anti-cancer treatment within 3 weeks or 5 blood half-lives (whichever is shorter).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests a new CAR-T cell therapy called GC012F for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this treatment can help control the disease.
This study tests a new drug called CM336 (a bispecific antibody) combined with standard care for people with high-risk multiple myeloma that came back quickly after first treatment. The goal is to see if it helps control the disease better.
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
This trial studies a new medicine called elranatamab combined with the chemotherapy drug cyclophosphamide for people with multiple myeloma that has returned or not responded to prior treatments. It may be a good option if you have aggressive or high-risk myeloma.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.